GSK2033

Research use only, not for human use.

GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively).

GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively).(In Vitro):GSK2033 dose-dependently inhibits basal transcription in full-length LXRα or full-length LXRβ cotransfection assays (IC50s: 17 nM and 9 nM, respectively). GSK2033 also effectively inhibits the transcription of an ABCA1 driven luciferase reporter dose-dependently (IC50s: 52 nM for LXRα and 10 nM for LXRβ). GSK2033 also suppresses the expression of both SREBP1 and fatty acid synthase (FASN).(In Vivo):GSK2033 (one month) treatment, does not have obviously effects on hepatic triglyceride levels. GSK2033 treatment also have no effects on plasma triglyceride levels .

——

Others

Other Targets

——

——

——

1221277-90-2

591.7

C29H28F3NO5S2

>98% (HPLC)

——

Cc1cc(C)c(c(C)c1)S(=O)(=O)N(Cc1ccc(o1)C(F)(F)F)Cc1ccc(cc1)-c1cccc(c1)S(C)(=O)=O

——

(-20℃)

With Ice Pack

≥ 2 years